Dosage and administration
apply locally as needed
apply locally as needed
Povidone-iodine 10%
(equivalent to 1% available iodine)
Antiseptic
In case of accidental ingestion, seek professional assistance or consult a poison control center immediately.
apply locally as needed
disodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, simethicone, water
1-800-633-5463
Manufactured by:
Aplicare Products, LLC
550 Research Parkway, Meriden, CT 06540 USA
Made in USA
REF: APL82-269
RL17HND
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 52380-1738-4 | ML - Milliliter | 52380-1738 | 81a22634-5bde-4b58-9222-4ee453db4ddf | 2 | 2013-09-04 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| POVIDONE-IODINE | ACTIVE INGREDIENT | 85H0HZU99M | 4 | |
| IODINE | ACTIVE MOIETY | 9679TC07X4 | 4 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 4 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 4 | |
| HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) | INACTIVE INGREDIENT | S38J6RZN16 | 4 | |
| NONOXYNOL-10 | INACTIVE INGREDIENT | K7O76887AP | 4 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 4 | |
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | INACTIVE INGREDIENT | 22ADO53M6F | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 52380-1738 | 52380-1738-4, 52380-1738-5 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| DIMETHICONE | 92RU3N3Y1O | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | IACT |
| HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) | S38J6RZN16 | IACT |
| NONOXYNOL-10 | K7O76887AP | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| WATER | 059QF0KO0R | IACT |
| POVIDONE-IODINE | 85H0HZU99M | ACTIM |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | TABLET, FOR SUSPENSION / ORAL | 60 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SOLUTION / INTRAVENOUS | 2460 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SUSPENSION / INTRAMUSCULAR | 36 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) | HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%) | S38J6RZN16 | SOLUTION / TOPICAL | 0.21 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 1751 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | SPRAY / NASAL | 1 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / RESPIRATORY (INHALATION) | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, LIQUID FILLED / ORAL | 106 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | OINTMENT / TOPICAL | 1 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 139.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / NASAL | 10 mg/1ml | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SUSPENSION / INTRA-ARTICULAR | 36 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION / INTRAMUSCULAR | 1751 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SUSPENSION / INTRASYNOVIAL | 3 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / OPHTHALMIC | 3 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SOLUTION / SUBCUTANEOUS | 0.11 %w/v | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | TABLET / ORAL | 96 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, SOLUBLE / ORAL | 2 mg | ||
| HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) | HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%) | S38J6RZN16 | SYRUP / ORAL | 2 mg/5ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SHAMPOO / TOPICAL | 5 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION, EXTENDED RELEASE / ORAL | 70 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY / NASAL | 22.3 mg/1ml | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TAMPON / VAGINAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) | HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%) | S38J6RZN16 | GEL / TOPICAL | 4 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION / ORAL | 200 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / IONTOPHORESIS | 168.1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) | HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%) | S38J6RZN16 | SPRAY / NASAL | 0.1 mg/0.2ml | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | SOLUTION / INTRAVENOUS | 381 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | AEROSOL, FOAM / TOPICAL | 0.09 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | MOUTHWASH / BUCCAL | 100 mg/1ml | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION / INTRAVENOUS | 381 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / TOPICAL | 6 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / VAGINAL | 60 mg | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, EMULSION / INTRAVENOUS | 0.28 %w/v | ||
| HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) | HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%) | S38J6RZN16 | SUSPENSION / ORAL | 100 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) | HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%) | S38J6RZN16 | SUSPENSION / TOPICAL | 0.69 %w/v | ||
| HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) | HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%) | S38J6RZN16 | TABLET, EXTENDED RELEASE / ORAL | 350 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SOLUTION / INTRATHECAL | 1 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d2195149-8a70-1445-e053-2995a90aec96 | 3a7874fb-e664-4e2c-b453-1aeee4832add | 2021-12-01 | Warnings | d2195149-8a70-1445-e053-2995a90aec96 3a7874fb-e664-4e2c-b453-1aeee4832add |
Adverse event summaries are temporarily unavailable. Other product information remains available.